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COSTS OF HEALTH CARE FOR HEPATITIS
C-INFECTED MEMBERS IN A MANAGED
CARE ORGANIZATION (MCO)
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The current literature provides limited information about
the cost-burden of Hepatitis C. OBJECTIVES: To iden-
tify all medical and pharmacy costs accrued by members
with Hepatitis C in a Medicaid MCO during 1999.
METHODS: Hepatitis C-infected patients were identified
from a database of continuously enrolled members from
an inner-city Medicaid MCO in Philadelphia during
1999 using ICD-9 codes indicative of Hepatitis C. Medi-
cal and pharmacy claims for these identified members
during this study period were obtained and analyzed. A
subanalysis comparing patients prescribed combination
ribavirin/interferon alfa-2b therapy with patients not pre-
scribed combination therapy was performed. Costs were
reported as reimbursements paid for medical claims and
pharmacy claims (AWP—14.5%). RESULTS: From a co-
hort of 73,869 members, 395 members (0.535%) met in-
clusion criteria for Hepatitis C. The mean age was 46.5
years (SD  9.5; range  4–81) and 213 (53.9%) were
male. These members had 17,507 medical claims result-
ing in payments of $4,075,082. Inpatient hospital ser-
vices accounted for 48% of these costs. There were
27,681 pharmacy claims that totaled $1,495,096. Sixty
patients received combination therapy, which totaled
$375,468 in pharmacy claims (n  444). Comparing pa-
tients prescribed combination therapy and patients not
prescribed combination therapy, medical costs were
$2,580/member and $11,702/member, respectively. In
addition, pharmacy costs were $8,610/member and
$2,920/member, respectively. Total costs in 1999 for pa-
tients prescribed combination therapy was $11,190/
member and for patients not prescribed combination
therapy was $14,622/member. These results were not ad-
justed for disease severity. CONCLUSIONS: Hepatitis C
is a very costly disease. Total health care costs to this
Medicaid MCO during 1999 for the 395 members identi-
fied with Hepatitis C exceeded $5.5 million. In addition,
total costs were less for members prescribed combination
ribavirin/interferon alfa-2b therapy compared with mem-
bers not prescribed combination therapy. Further investi-
gation is needed to explain the observed differences in
health care expenditures between these two populations.
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COST-EFFECTIVENESS OF INTERFERON ALFA 
THERAPY FOR CHRONIC HEPATITIS C 
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OBJECTIVE: To estimate the lifetime benefits and costs
of interferon alfa therapy for active hepatitis C with cir-
rhosis (HC), cost-effective analysis was carried out.
METHODS: Cost-effectiveness analysis (CEA) and cost-
utility analysis (CUA) were carried out to estimate the
lifetime benefits and costs of interferon alfa therapy (IFA)
for HC. A Markov model base on a randomized con-
trolled trial was developed. As a comparator, conven-
tional therapy (CV) was used. A societal viewpoint was
adopted for the estimation of costs, and both direct and
indirect costs were evaluated. A Monte Carlo simulation
was done to evaluate a confidence interval of cost-effec-
tiveness or cost-utility ratio. Quality of life (utility) was
measured by a time-trade off method among HC pa-
tients. RESULTS: At lifetime follow-up among 40 years
of men, expected life years (15.2 years) for IFA were
longer than those (9.0 years) for CT. Moreover, expected
QALYs (9.86) for IFA were longer than those (5.30) for
CT. On the other hand, expected costs ($548,500) for
IFA were higher than those ($459,000) for CT. The in-
cremental cost per life-year gained for IFA was $4,900
(discount rate of cost and effectiveness: 5%). The incre-
mental cost per QALY gained was $6,240. Sensitivity
analysis for age, costs, and health outcomes confirmed
robustness of these results. CONCLUSION: On the basis
of this analysis, IFA for HC should prolong length and
quality of life at a reasonable incremental costs, from a
societal perspective.
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OBJECTIVES: To estimate differences in adjusted hospi-
tal length of stay (LOS) between linezolid and vancomycin
using multivariate survival analysis. Linezolid’s bioequivalent
IV and oral formulations may enable earlier hospital dis-
charge compared to vancomycin treatment. METHODS:
460 hospitalized patients with suspected/confirmed me-
thicillin-resistant Staphylococcus infections were treated
with either linezolid (LZD) or vancomycin (VAN) in a
randomized controlled trial. Covariate imbalances be-
tween treatment groups were tested using t-tests and chi-
square tests. Multivariate Cox proportional hazards and
several parametric models for LOS were tested for best fit
using the Akaike Information Criteria and log-likelihood
ratio statistics. The Cox proportional hazards assump-
tion was rejected (p  .05); log-logistic survival models
fit best. The log-logistic estimates are used to create two
alternative adjusted survivorship functions, one based on
individual corrections to LOS (Individual correction),
and the other based on means of the predicted survivor-
